Frontlight ResearchEarly access
Active, not recruitingNo phase
McNeel Eye Center Corneal Crosslinking Study
Key facts
- Who runs it
- McNeel Eye Center
- Where
- Boise, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- People taking part
- 100 people, planned
- Started
- 1 Sept 2016
- Ended
- 31 Dec 2025
- Type of study
- Interventional
- Treatments tested
- Crosslinking using UV light of two different fluence rates
- Record updated
- 6 April 2025
Who can take part
- Age
- 15 years to 50 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Males or females between the ages of 15 and 50 with keratoconus diagnosed topographically with or without other corneal ectatic disease
Who cannot take part
- Prior corneal transplantation, pregnancy, inability or unwillingness to adhere to follow up protocol
Where in United States
- McNeel Eye CenterBoise, United States
About the trial
What the trial wants to find out
This study will investigate the effectiveness in treating keratoconus, pellucid marginal degeneration and post LASIK iatrogenic ectasia utilizing fluence rates and treatment times of Corneal Cross Linking other than the original FDA approved protocol of 3mw/cm2.
The group in the trial
- Crosslinking at different fluence ratesTreatment being tested
The study will investigate the effectiveness of Transepithelial riboflavin .25% treated with Ultraviolet light at fluence rates of 9mw/cm2 and 18mw/cm2 in the treatment of diagnosed keratoconus, pellucid marginal degeneration or post-LASIK ectasia.
Treatment: Crosslinking using UV light of two different fluence rates
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Study of Effectiveness and Safety of Transepithelial Collagen Cross-linking at Varying Fluence Levels.
- Record updated
- 6 April 2025